OncoMatch/Clinical Trials/NCT06880029

Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy

Is NCT06880029 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies non-drug interventions for triple negative breast cancer (tnbc).

Phase 1/2RecruitingCentro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.NCT06880029Data as of Jun 2026Location: Portugal

CIRCADIAN is a prospective randomized clinical trial designed to evaluate the impact of pembrolizumab infusions' time-of-day on pathological complete response (pCR) rate among TNBC patients undergoing neoadjuvant treatment.

Check if I qualify

Extracted eligibility criteria

Cancer type

Triple-Negative Breast Cancer

Breast Carcinoma

Disease stage

Required: Stage II, III

Demographics

Ages ≤ 75

Female only

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06880029 currently recruiting?

Yes, this trial is currently recruiting patients.

What disease stage is eligible?

Stage II or III is required.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Is this trial open to male patients?

No. This trial enrolls female patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify

Triple-Negative Breast Cancer trials Breast Carcinoma trials